Company intelligence / Profile preview
Shanghai Benemae Pharmaceutical Corporation
Shanghai, Shanghai Municipality, Chinabenemae.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Benemae developed and commercialized beinaglutide, a fully human GLP‑1 analog approved in China since December 2016 for type II diabetes. The company has several pipeline programs targeting obesity and metabolic diseases at preclinical or clinical stages. Its gene engineering tandem technology underpins its innovation in peptide therapeutics. Clinical results show efficacy in glycemic control and weight loss among Chinese patients with type II diabetes.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Recombinant polypeptidesSynthetic peptidesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
No major international pharma partnerships disclosed as of latest available data.
Beyond the preview
Go deeper on Shanghai Benemae Pharmaceutical Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Benemae Pharmaceutical Corporation.